Seeking Alpha


Send Message
View as an RSS Feed
View candooman's Comments BY TICKER:
Latest  |  Highest rated
  • Sirius XM re-ups CFO Frear for three years [View news story]
    At $4 stock price, his options works out to about $20 million a year for 3 years. I hope this incentivizes him to do what ever is needed to raise the stock price to $5 so he get $15 million more.... and soon!
    Jul 8, 2015. 12:29 PM | 4 Likes Like |Link to Comment
  • Third patient receiving InVivo's Neuro-Spinal Scaffold shows encouraging progress, shares up 10% premarket [View news story]
    Paolo, regaining some control of ones bladder and anus makes a big difference in life. It makes it a lot easier for a care giver not to have to deal with people's excrement. This makes a big improvement in quality of life!
    Jul 6, 2015. 01:42 PM | 7 Likes Like |Link to Comment
  • Is Ocata Therapeutics' Lackluster Debut A Buy Or Sell? [View article]
    Well stated! We need to trust this management is better than the last one and truly cares for the long term well being of the company. We got to have faith in this management.
    Jul 2, 2015. 11:01 AM | Likes Like |Link to Comment
  • Is Ocata Therapeutics' Lackluster Debut A Buy Or Sell? [View article]
    DWD, as far as I can see following ACTC/OCAT for more than 5 years, the science is settled. The injection of cells works and it is safe. As a minimum, it arrests further deterioration of the eyes, a big plus if AMD is caught early since loss of sight is minimized. On some subjects, especially in the 150,000 cell dosage and above, the eyesight improved enough to allow the subject to have normal activities. What Phase 2 trials will do is prove the efficacy of the treatment at dosages of between 200,000 and 300,000 cells. The question is not is it good but how good is it?

    Because of criticality to young Starrguard patients, that part of the Ph 2 trials is designated as Pivotal, meaning, if it is shown to be effective, it will quickly gain FDA approval. I believe the FDA and OCAT have now agreed on the end points and the definition of success; this took a lot of time to negotiate. By this time next year, this treatment for SAMD may be approved. If so, OCAT will be making money, lots of it. This cell treatment can be applied worldwide.

    The risk of OCAT's treatment failing is zero. Many investors have not realized this yet. If you want to gain more info, listen to the presentation webcast on July 8, Wednesday at 8:15 PST at their site.
    Jul 2, 2015. 10:19 AM | 1 Like Like |Link to Comment
  • Axion Power Concentrator 399: June 8, 2015 [View instapost]
    Today LCB International signed a Letter of Intent with Axion to manufacture and sell PbC batteries exclusively in China and its territories. The head of LCB (Chinese) worked in the Delco division of GM in China and another battery company. He has been a Venture Capitalist for many years (successful) and also has a graduate degree from MIT. Because he holds a PhD and is investing in Axion, would you say AXION will now be a successful company? What opportunities did he see in Axion that Americans and Germans (BMW) failed to see?
    Jun 15, 2015. 05:22 PM | 2 Likes Like |Link to Comment
  • Axion Power up 154.6% on potential Chinese licensing deal [View news story]
    Shareholders will get proxy statement asking for approval of deal -- maybe in the next 3 weeks. Even with 20% dilution, it will likely be approved; the alternative is possible BK..... APW is low on operating capital. If LCB International has potential big customers now ( very possible ) and after the deal is signed and approved and get their big order(s) ......... we are off to the races! Otherwise, it is BK!
    Jun 15, 2015. 01:12 PM | 1 Like Like |Link to Comment
  • Why Truckers Are Slow To Embrace CNG Fuel Systems [View article]
    It did not help that the new CEO who I thought was capable of taking Axion heading in the right direction suddenly died. If they do not get a sizable order for their PcB batteries in the next six months, it might be the end of Axion as a company. It is very difficult for a customer to decide to buy their products knowing the company may go belly up in a year or less.
    Jun 9, 2015. 05:19 PM | Likes Like |Link to Comment
  • InVivo Therapeutics’ Neuro-Spinal Scaffold Receives 2015 Becker’s Healthcare Spine Device Award [View article]
    Getting the 3rd patient into is taking a long time. I guess, to get a person who gets into:

    (1) an accident and
    (2) has spinal cord paralyzing injury resulting in a para or quadra state,
    (3) and is taken into one of only 4 designated study hospitals in the country and
    (4) getting their consent to be included in the study
    (5) while unable to think clearly

    are requirements proving difficult to fulfill. Of course we do not want people to have an accident so they can be in the study. But Summer is here, more people are driving motorcycles....
    Jun 2, 2015. 09:39 AM | Likes Like |Link to Comment
  • Why An Old Warning About Stocks Feels More Ominous This Year [View article]
    Amen. Sell in May not only means selling what you own, which raises your cash holdings, before it goes down and loses value. That same decline in value of most stocks, presents you an opportunity (now with some raised cash on hand) to buy the stocks you want at a lower or perhaps even at a bargain price.
    May 26, 2015. 09:21 AM | 2 Likes Like |Link to Comment
  • DOJ may withdraw agreement not to prosecute UBS [View news story]
    The DOJ changes its mind after seeing the banks with non-prosecute agreement were taking advantage of their agreement to manipulate interest rates. In principle, if a party to an agreement engages in conduct contrary to the agreement then the agreement is no longer valid. The DOJ cannot continue to allow the bank's bad behavior while pursuing only the other banks who do not have the non-prosecute agreement. The only way to change bankers behavior is to prosecute them. They cannot be given a pass (non-prosecute agreement) and allow to practice bad behavior. So, the DOJ is correct in changing its mind. Fleecing of customers is never a good thing, contract or no contract.
    May 13, 2015. 09:39 AM | Likes Like |Link to Comment
  • Sirius XM: Explaining The 1 Cent 'Miss' In Q1 Earnings [View article]
    Thanks Stephen for running this "continuing education" courses for us none accounting types, simple folks. Your clear explanations is a delight to read.
    May 4, 2015. 12:20 PM | 6 Likes Like |Link to Comment
  • Sirius XM: Based On Earnings Shares Could See 50% Upside Over The Next 2 Years [View article]
    Could the earnings miss be due to increase in payments on loans taken out to buy back shares?
    Apr 28, 2015. 11:37 AM | Likes Like |Link to Comment
  • Sirius XM: Why I'm Buying The Stock Despite Its First-Quarter Earnings Miss [View article]
    I am waiting for the CC on this QTR Report. I am wondering if they will get Fiat-Chrysler to signup for SIRI connect? Except for GM and Ford which have their own service, SIRI has no US car makers in their list of customers.
    Apr 28, 2015. 09:56 AM | Likes Like |Link to Comment
  • Sirius XM: Why Apple Still Remains A Likely Suitor [View article]
    Apple takeover will. like Comcast, run into antitrust objections...... loss of competition. But offers from Google or MS will likely be acceptable to the FTC.
    Apr 27, 2015. 10:02 AM | 3 Likes Like |Link to Comment
  • Athersys's MultiStem therapy fails to meet primary endpoint [View news story]
    We will have to wait for the presentation on May 11. It should be an interesting meeting. If you are an optimist, load up a bit on the possibility of a good plan being discussed during the meeting. Otherwise, hold.
    Apr 21, 2015. 10:18 AM | Likes Like |Link to Comment